Thursday, 19 April 2018 - 10:43
  • it
  • de
  • en
  • fr


European Commission approves AstraZeneca’s Tagrisso

AstraZeneca has announced that the European Commission has granted marketing authorization for Tagrisso (osimertinib),which will be available in 40 and 80mg doses. The product, in tablets, is to be administered once-daily for the treatment of adult patients with locally-advanced or…

Astellas pursuing M&A again: Ogeda acquired for €800m

Japan-based Astellas Pharma announced today before trading opened in Tokyo that it has acquired Belgium-based Ogeda SA for €800m. Ogeda develops novel drugs which bind to GPCR receptors. Its lead investigational product is fezolinetant, a non-hormonal therapy which has delivered…

New FDA approval for Tagrisso (AstraZeneca)

FDA approved AstraZeneca’s Tagrisso (osimertinib) for the treatment of patients with metastatic EGFR-positive NSCLC. Moreover, these patients have already undergone TKI (tyrosine kinase inhibitor) therapy. Tagrisso is currently the only approved treatment in the US for patients with EGFR who…